Drug Profile
Entacapone - Novartis/Orion
Alternative Names: Comtan; Comtess; OR 611Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Orion
- Developer Bristol-Myers Squibb; Eisai Co Ltd; Novartis; Orion
- Class Antiparkinsonians; Catechols; Nitriles; Nitrophenols; Small molecules
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
- Discontinued Restless legs syndrome
Most Recent Events
- 31 Dec 2019 Lotus Pharmaceutical acquires marketing and distribution rights for entacapone from Orion Pharma in Hong Kong, Philippines, South Korea and Taiwan
- 25 Apr 2019 Novartis returns marketing rights in certain European countries for Parkinson's disease to Orion
- 16 Feb 2017 Eisai acquires marketing rights for entacapone from Orion Pharma in China